A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger.

Experimental Hematology
Rodwell MabaeraChristopher H Lowrey

Abstract

A major goal of hemoglobinopathy research is to develop treatments that correct the underlying molecular defects responsible for sickle cell disease and beta-thalassemia. One approach to achieving this goal is the pharmacologic induction of fetal hemoglobin (HbF). This strategy is capable of inhibiting the polymerization of sickle hemoglobin and correcting the globin chain imbalance of beta-thalassemia. Despite this promise, none of the currently available HbF-inducing agents exhibit the combination of efficacy, safety, and convenience of use that would make them applicable to most patients. The recent success of targeted drug therapies for malignant diseases suggests that this approach could be effective for developing optimal HbF-inducing agents. A first step in applying this approach is the identification of specific molecular targets. However, while >70 HbF-inducing agents have been described, neither molecular mechanisms nor target molecules have been definitively verified for any of these compounds. To help focus investigation in this area, we have reviewed known HbF-inducing agents and their proposed mechanisms of action. We find that in many cases, current models inadequately explain key experimental results. By integra...Continue Reading

References

Dec 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·T PapayannopoulouG Stamatoyannopoulos
May 1, 1978·Cell·L Sealy, R Chalkley
Sep 1, 1976·British Medical Bulletin·W G Wood
Jun 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·T H PapayannopoulouG Stamatoyannopoulos
Jan 1, 1990·American Journal of Hematology·D P LiuY W Huang
Jan 1, 1990·The American Journal of Pediatric Hematology/oncology·G StamatoyannopoulosT Papayannopoulou
Jun 1, 1985·The Journal of Clinical Investigation·N L LetvinD G Nathan
Jan 1, 1985·Annals of the New York Academy of Sciences·G StamatoyannopoulosT Papayannopoulou
Dec 19, 1985·The New England Journal of Medicine·R VeithG Stamatoyannopoulos
Nov 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S P PerrineY W Kan
Feb 7, 1985·The New England Journal of Medicine·S P PerrineD V Faller
Feb 1, 1985·The Journal of Clinical Investigation·R K HumphriesA W Nienhuis
Nov 1, 1966·The American Journal of Medicine·D G Nathan, R B Gunn
Jul 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·J DeSimoneD Zwiers
Dec 9, 1982·The New England Journal of Medicine·T J LeyA W Nienhuis
Mar 5, 1983·Lancet·J B CleggW F Bodmer
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·T J LeyW F Anderson
Sep 1, 1994·The Journal of Pediatrics·F M Hajjar, H A Pearson
Jan 14, 1993·The New England Journal of Medicine·S P PerrineN F Olivieri
Sep 16, 1993·The New England Journal of Medicine·C H Lowrey, A W Nienhuis
Jun 15, 1995·The New England Journal of Medicine·G D SherN F Olivieri
Jun 9, 1994·The New England Journal of Medicine·O S PlattP P Klug
Jul 1, 1994·American Journal of Hematology·P K SenguptaJ DeSimone
Jan 1, 1996·Blood Cells, Molecules & Diseases·S TorkelsonS P Perrine
Nov 3, 1998·Clinical Pharmacology and Therapeutics·M de L NascimentoE M Coutinho
Apr 25, 2000·Blood Cells, Molecules & Diseases·M Domenica CappelliniG Fiorelli
May 12, 2000·Critical Care Medicine·T ObataM B Yaffe
May 16, 2000·Biochemical Pharmacology·N BianchiR Gambari
Aug 1, 1996·Social History of Medicine : the Journal of the Society for the Social History of Medicine·M W Weatherall
Feb 14, 2002·British Journal of Haematology·Mark T GladwinGriffin P Rodgers
Feb 15, 2002·Current Opinion in Hematology·Stanley L Schrier
Apr 20, 2002·Lancet·Michael AidooVenkatachalam Udhayakumar

❮ Previous
Next ❯

Citations

Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Wenhu PiDorothy Tuan
Mar 5, 2011·Current Opinion in Hematology·Patrick T McGann, Russell E Ware
Mar 12, 2013·Current Opinion in Hematology·Michael R Tallack, Andrew C Perkins
Apr 6, 2011·Blood·Elizabeth R Macari, Christopher H Lowrey
May 2, 2013·Haematologica·Antonella Ronchi, Sergio Ottolenghi
Apr 8, 2011·World Journal of Gastroenterology : WJG·Roberto Berni CananiAntonio Calignano
Jan 1, 2009·Mediterranean Journal of Hematology and Infectious Diseases·Marco Gabbianelli, Ugo Testa
Aug 4, 2011·International Journal of Cell Biology·Laura J NortonMerlin Crossley
Dec 10, 2013·Blood Cells, Molecules & Diseases·Emily K SchaefferChristopher H Lowrey
Sep 10, 2010·Advances in Hematology·Luciano CianettiNadia Maria Sposi
Mar 19, 2016·Blood·Christopher H Lowrey
Jul 1, 2015·British Journal of Haematology·Kenneth I Ataga, Jonathan Stocker
Aug 31, 2011·Evidence-based Complementary and Alternative Medicine : ECAM·Hui LiKwok Pui Fung
Jul 29, 2015·BMC Medical Genomics·Duyen A Ngo, Martin H Steinberg
Apr 15, 2011·Blood·Idowu AkinsheyeMartin H Steinberg
Dec 20, 2011·Blood Reviews·Anna Rita MigliaccioCarolyn Whitsett
Jan 21, 2012·Blood Cells, Molecules & Diseases·Angela RissoGuglielmo Antonutto
Sep 4, 2014·Asian Pacific Journal of Tropical Biomedicine·Abbas NajjariAli Asghar Ahmadi
Mar 31, 2016·Experimental Biology and Medicine·Winfred C Wang
May 10, 2017·Omics : a Journal of Integrative Biology·Alexandra KolliopoulouGeorge P Patrinos
Feb 6, 2017·Lancet·Russell E WareMiguel R Abboud
May 20, 2015·Molecular and Cellular Biology·Yu-Chi ChouChe-Kun James Shen
Jan 24, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Kasey S K ChanJim Vadolas
Aug 30, 2019·Hemoglobin·Titilope A AdeyemoAdekunle D Adekile
Mar 14, 2020·Current Opinion in Hematology·Lei YuJames D Engel
Dec 29, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Mark RoosjenJim Vadolas
Apr 10, 2014·Current Opinion in Hematology·Jane-Jane Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis